Major Symptom Score Utility Index for patients with acute rhinosinusitis Revicki DA, Margolis MK, Thompson CL, Meltzer EO, Sandor DW, Shaw JW. Am J Rhinol Allergy. 2011 May;25 (3):99-106.

Donald E. Stull, Arvind Narayana, Tiffany Burch, David W. Sandor, Abstract, Validation Analyses of the Patient Assessment of Function and Clinician Assessment of Patient Function in Patients with Breakthrough Pain. Presented at the 30th Annual Scientific Meeting of the American Pain Society, May 19-21, 2011, Austin, TX.

Donald Stull, Katherine Houghton, Patricia van Hanswijck de Jonge, Christopher Kocun, David W. Sandor, Development of the US National Frequent Heartburn Index (FHBI) and Associated Composite Score. Quality of Life Research (2011) 20:1023-1034.

Donald Stull, Katherine Houghton, Patricia van Hanswijck de Jonge, Christopher Kocun, David W. Sandor, Development of the US National Frequent Heartburn Index (FHBI) and Associated Composite Score Presented at the ISOQOL 17th Annual Conference, October 27 – 30 2010; London, England

Stull, Donald E., PhD, van Hanswijck de Jonge, Patricia, MSc, PhD, Winnette, Randall, BS, Fennerty, M. Brian, MD, Farber, Michael, MD, Ferguson, David, PhD, MD, FACCP, Fourcroy, Jean, MD, PhD, MPH, Sandor, David W., DSW (2010) Psychosocial Effects of Frequent Heartburn: A Nationally Representative Survey of Frequent Heartburn Sufferers in America. Presented at the Preventive Medicine 2010 Annual Meeting February 17–20, 2010.

James W. Shaw, PhD, PharmD, MPH, Gregory Reardon, PhD, David W. Sandor, DSW, Raymond C. Rosen, PhD, and David M. Ferguson, MD, PhD, Validation of Stopwatch Measurements of Erection Duration against Responses to the Sexual Encounter Profile and International Index of Erectile Function in Patients Treated with a Phosphodiesterase Type 5 Inhibitor, J Sex Med. 2010 Jan 26. [Epub ahead of print]

Dranitsaris, G., Rayson, D., Vincent, M., Chang, J., Gelmon, K., Sandor, D. & Reardon, G., Identifying Patients at High Risk for Neutropenic Complications During Chetherapy for Metastic Breast Cancer with Doxorubicin or Pegylated Pisosomal Doxorubicin:The Development of a Prediction Model. American Journal of Clinical Oncology .2008 Aug; 31(4):369-74

Dranitsaris, G., Rayson, D., Vincent, M., Chang, J., Gelmon, K., Sandor, D. & Reardon, G. (2007)Treatment of Metastatic Breast Cancer with DoxorubicinOr Pegylated Liposomal Doxorubicin: The Development of a Model toIdentify Patients at High Risk for Cardiac Toxicity.American Society of Clinical Oncology (ASCO) Breast Cancer Symposium.

Dranitsaris, G., Rayson, D., Vincent, M., Chang, J., Gelmon, K., Sandor, D. & Reardon, G., The development of a Predictive Model to Estimate Cardiotoxic Risk for Patients with Metastatic Breast Cancer receiving Anthracyclines. Breast Cancer Research and Treatment, 443-450, Volume 107, Number 3 / February, 2008

Vernon MK, Stull DE, Crespi S, Sandor D. (2007) The Progression of Congestion Symptoms and their Impacts: A Naturalistic Study. Allergy and Clinical Immunology International. Allergy Clin Immunol Int: J World Allergy Org, vol. 19, no. 6, pp. 225-232

Stull DE, Vernon MK, Canonica GW, Crespi S, Sandor D. (2007) Monitoring Nasal Congestion: Using the Congestion Quantifier 7-item Test to Monitor Change in Patient Symptoms and their Impact.Allergy and Asthma Proceedings, Volume 29, Number 3, May-June 2008 , pp. 295-303

Shaw, J., Reardon, G., Sandor, D., Rosen, R. Ferguson, D., (2007) Validation of Electronic Stopwatch Measurements of Erection Duration Against Responses to the Sexual Encounter Profile and International Index of Erectile Function. 10th Congress of the European Society (ESSM) for Sexual Medicine.

Singer, M., Sandor, D. & Reardon, G. (2007) Cost Effectiveness of Pegylated Lipisomal Doxorubicin VS Conventional Doxorubicin in Avoidance of Cardiotoxicity for Metastatic Breast Cancer in the First Treatment Year. International Society for Pharmacoeconomics (ISPOR) 10th Annual European Congress.

Stull, D., Canonica, G., Sandor, D., Crespi, S., Vernon, M. (2007) Monitoring Nasal Congestion: Using the Congestion Quantifies 7-item Test (CQ&) to Assess Change in Patient Symptoms and their Impact. Internaional Society for Quality of Life Research (ISOQL) Conference on Patient Reported Outcomes in Clinical Practice. June 24-26, 2007. Budapest,Hungary.

Stull, D., Canonica, G., Sandor, D., Crespi, S., Vernon, M. (2007) The Congestion Quantifier: A Patient-Reported Outcome Tool to Screen for and Monitor Nasal Congestion. XXVI European Academy of Allergology and Clinical Immunology (EAACI) Congress. June 9-13, 2007. Goteborg, Sweden.

Vernon, M., Crespi, S., Sandor, D. & Stull, D. (2007)The Progression of Congestion Symptoms and Their Impacts. XXVI European Academy of Allergology and Clinical Immunology (EAACI) Congress. June 9-13, 2007.Goteborg, Sweden. D.E. Stull*1, E.O. Meltzer2, D.

Sandor3, S. Crespi4,M.K.Vernon1,1. Bethesda, MD; 2.San Diego, CA; 3. Hackensack, NJ; 4. Kenilworth, NJ The CQ5: A Monitor for Nasal Congestion.2007 Annual Meeting of the American College of Allergy, Asthma & Immunology. Dallas, TX, November 8-14,2007.

Canonica GW, Stull DE, Sandor D, Crespi S, Vernon MK. Patient-administered screening tool for nasal congestion has sensitivity to monitor treatment progress: seven-item Congestion Quantifier (CQ7). Sociedad Latinoamericana de Alergia e Inmunología [Latin American Society of Allergy & Immunology]. August 17-20, 2007; Buenos Aires, Argentina

Stull DE, Canonica GW, Sandor DW, Crespi S, Vernon MK. Monitoring Nasal Congestion: Using the Congestion Quantifier 7-Item Test (CQ7) to Assess Change in Patient Symptoms and their Impact. Presented at the ISOQOL 2007 “PROs in Clinical Practice,” June 24-26, 2007. Budapest, Hungary.

Donald E. Stull, PhD 1, Michael Schaefer, MA 2, Simone Crespi, MPH 3, David W. Sandor, DSW 4, Relationship of Nasal Congestion and Ocular Symptoms with Patient Reported- Sleep, Mood, and Productivity. Presented at the 2008 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), Seattle, WA, November 6–11, 2008.